

R.L. MacMurray 🇬🇧
12.9K posts

@DeviateDefiant
🏴🏴🇩🇪 Director/Developer 🍃 Cannabis Patient 🦁 @RestoreBritain_ ✈️ 45 Countries 🇺🇸 20 States “Touch not the cat, but a glove.”









The A303 Stonehenge tunnel has been scrapped after years of planning. £180 million. Gone. Not a single mile built. Not a single benefit delivered. Just taxpayer money burned. Who is actually held accountable for this?




Imagine seeing British people at prayer and thinking “this is a great chance to stoke fear, hatred and division”. People who do that should have no place in British politics. Freedom to worship is a fundamental British value – one the Conservative Party used to believe in.

🔴 Under the deal, they could live and work or study in Britain for a set period Read more about the new arrangement ⬇️ telegraph.co.uk/politics/2026/…

Next day or two we'll be adding the first pharmacy formulary (outside of GAP) that's undercutting RRPs by default 👌




@devisridhar 1,500,000+ adverse reactions to COVID vaccines recorded in the UK - how many went unreported? No medical professional can claim that potential temporary mild illness from Omicron, is more dangerous than potential injury, maiming or death via vaccine. You are the health crisis.

Coming soon to a market near you. When @GrowGroupUK's Grow Access Project (GAP) relaunched recently offering 10% off any med via Pharmacy Space – then coupled with <£4/g launches... ...the UK is heading back towards 90s BM pricing in general. More new products proportionately than new patients = supply > demand = price drops, just to compete. What we're also likely to see this year is the beginning of the big price war to undercut RRPs on meds, because the race to the bottom on clinic fees is almost over; and it's something normalised in other large medical markets. At this point you effectively have to be <£10pm for clinic fees, or you can't increase your patient base adequately or see major market adoption. Why choose any newbie company over an established player at this point, let alone one more expensive? There's very few exceptions to this rationale for patients. When you can't compete on clinic pricing/offers (because you couldn't increase you patient numbers quickly/sufficiently enough to be profitable), the only port of call is to offer some other competing 'value proposition' to patients, whereby your service ultimately ends up cheaper in other ways. To patients, that can only mean cheaper medication or wider availability – every pharmacy legally cannot be compelled to sell at RRP whatsoever, due to pricing-fixing and anti-competitive laws. This has ultimately been exactly what's played out in both the German and Australian markets, with pharmacies enforcing their legal right to sell at whatever price they want. We've built our system around being able to handle all the RRP undercutting we expect to see going forward, and just hope our market analysis proves accurate overall. Because ultimately, then, it's patients that win overall 🏆





